Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

Jane N. Winter, MD
Published: Tuesday, Mar 27, 2018



Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial in diffuse large B-cell lymphoma (DLBCL; NCT03391466).

The ZUMA-7 study is evaluating the efficacy of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) compared to standard of care therapy in patients with relapsed/refractory DLBCL. In this phase III randomized, open-label, multicenter study, patients will be randomized to receive axi-cel or standard of care second-line therapy following treatment with first-line rituximab (Rituxan) and anthracycline-based chemotherapy.

Winter says that immunotherapy may be the best strategy for patients with relapsed/refractory DLBCL. This is very exciting for these patients, Winter explains, because there are not many therapeutic choices for this population.


Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial in diffuse large B-cell lymphoma (DLBCL; NCT03391466).

The ZUMA-7 study is evaluating the efficacy of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) compared to standard of care therapy in patients with relapsed/refractory DLBCL. In this phase III randomized, open-label, multicenter study, patients will be randomized to receive axi-cel or standard of care second-line therapy following treatment with first-line rituximab (Rituxan) and anthracycline-based chemotherapy.

Winter says that immunotherapy may be the best strategy for patients with relapsed/refractory DLBCL. This is very exciting for these patients, Winter explains, because there are not many therapeutic choices for this population.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x